The NR3C1 Knockout Raji Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B-lymphocyte cell line, engineered for targeted disruption of the NR3C1 gene. This gene-edited model provides a versatile loss-of-function tool for studying glucocorticoid receptor biology in a lymphoma context. The polyclonal format ensures broad representation of editing events without clonal selection, making it appropriate for functional genomics, pooled screening, and mechanistic studies that require an unbiased cellular pool.
The Raji parental cell line is an Epstein-Barr virus (EBV)-positive lymphoblastoid line established from Burkitt??s lymphoma. As a model of aggressive B-cell malignancy, Raji cells display constitutive NF-??B signaling and inherent apoptosis resistance, features that are directly influenced by glucocorticoid signaling. This cellular background is extensively used to investigate B-cell lymphomagenesis, EBV latency, and therapeutic responses, making it a relevant host for dissecting NR3C1 function in immune evasion and cell survival.
NR3C1 encodes the glucocorticoid receptor (GR), a ligand-activated transcription factor that responds to cortisol and dexamethasone. In the unliganded state, GR is sequestered in the cytoplasm by a chaperone complex comprising HSP90, HSP70, and FKBP51. Hormone binding triggers nuclear translocation and binding to glucocorticoid response elements, inducing genes such as GILZ (TSC22D3) and FKBP5. Through transrepression, GR also suppresses NF-??B and AP-1, integrating glucocorticoid signaling with immune modulation and apoptosis.
Functional NR3C1 signaling in Raji cells promotes glucocorticoid-induced apoptosis and dampens NF-??B-driven survival pathways. Deletion of NR3C1 removes this regulatory checkpoint, generating a pertinent model for dissecting glucocorticoid resistance mechanisms in B-cell lymphoma. The knockout allows precise evaluation of NF-??B and AP-1 contributions to proliferation and survival independent of GR-mediated transcriptional control, and facilitates high-content screening for compounds that re-sensitize lymphoma cells to glucocorticoids.
These NR3C1 knockout polyclonal cells support a wide array of functional assays including Annexin V/PI apoptosis measurements, RT-qPCR for downstream effectors GILZ and FKBP5, and dual-luciferase reporter assays to monitor GRE and NF-??B activity. Western blotting for NR3C1 and associated proteins, MTT cell viability assays, and transcriptome profiling by RNA-seq further enable detailed phenotypic and mechanistic analyses. This product is ideally suited for studies of glucocorticoid resistance, B-cell lymphoma biology, and immunomodulatory drug screening. For technical assistance and ordering information, please contact Ascent Research.
